VCEL Vericel Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 887359 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY25.3%
TTM net income YoY154.6%
TTM EPS YoY146.2%
Revenue 3-yr CAGR20.5%
Net income 3-yr CAGR—
Margins
Gross margin74.5%
Operating margin8.3%
Net margin10.3%
FCF margin17.9%
EBITDA margin12.4%
Returns
ROE9.4%
ROA6.9%
ROIC (approx.)9.0%
Asset turnover0.67x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio5.13x
Interest coverage42.01x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue2.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $276.26M | $237.22M |
| Cost of revenue | $70.66M | $65.12M |
| Gross profit | $205.60M | $172.11M |
| R&D expense | $27.56M | $24.80M |
| SG&A expense | $166.99M | $142.79M |
| Operating income | $11.04M | $4.52M |
| Interest expense | $630,000 | $614,000 |
| Pretax income | $17.38M | $10.51M |
| Income tax | $859,000 | $148,000 |
| Net income | $16.52M | $10.36M |
| EBITDA | $22.59M | $10.02M |
| EPS (basic) | 0.33 | 0.21 |
| EPS (diluted) | 0.32 | 0.20 |
| Weighted avg. shares (diluted) | 52.15M | 51.68M |
| Balance sheet | ||
| Cash & equivalents | $100.09M | $85.05M |
| Short-term investments | $37.41M | $41.69M |
| Receivables | $84.63M | $61.38M |
| Inventory | $17.56M | $17.37M |
| Current assets | $247.44M | $212.78M |
| PP&E, net | $108.40M | $103.16M |
| Intangibles | $5.62M | $6.25M |
| Total assets | $487.97M | $432.72M |
| Current liabilities | $49.15M | $50.29M |
| Total liabilities | $133.33M | $140.75M |
| Shareholders' equity | $354.64M | $291.97M |
| Shares outstanding | 50.62M | 49.63M |
| Cash flow statement | ||
| Operating cash flow | $51.91M | $58.16M |
| Capital expenditure | $27.16M | $63.97M |
| Free cash flow | $24.75M | -$5.81M |
| Investing cash flow | -$43.94M | -$79.03M |
| Financing cash flow | $7.07M | $19.05M |
| Depreciation & amortization | $11.54M | $5.50M |
| Stock-based compensation | $38.77M | $36.49M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.